

WELCOME

Clozapine & LAI Virtual Forum

February 1, 2023 | 4:00 – 4:45 pm ET

The Clozapine & LAI Virtual Forum is an all-new, peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians.

It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.

TODAY'S TOPIC:

Comprehensive Screening for Antipsychotic-Induced Movement Disorders Via Telehealth

MODERATORS

Donna Rolin, PhD, APRN

Dr. Donna Rolin is Clinical Associate Professor and the Psychiatric Mental Health Nurse Practitioner (PMHNP) Program Director at the University of Texas. She serves as SMI Adviser Nursing Expert.

Oliver Freudenreich, MD, FACLP

Dr. Oliver Freudenreich is an Associate Professor of Psychiatry at Harvard Medical School and the Co-Director of the Psychosis Clinical and Research Program at Massachusetts General Hospital. He serves on the SMI Adviser LAI Workgroup.

Sarah MacLaurin, MSN, APRN

Ms. Sarah MacLaurin is a PMHNP at the Freedom Trail, which is a collaboration between North Suffolk Mental Health Association and Massachusetts General Hospital's Schizophrenia Clinical and Research Program. She serves on the SMI Adviser LAI Workgroup.

Megan Ehret, PharmD, MS, BCPP

Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Pharmacy Practice and Science. She is a Past-President of the College of Psychiatric and Neurologic Pharmacists. She serves as SMI Adviser Pharmacy Consultant.

Discussion Questions for Virtual Forum: Comprehensive Screening for Antipsychotic-Induced Movement Disorders Via Telehealth

- How often do you conduct AIMS (or other TD) exams at LAI injection appointments?
 - Are there challenges for those patients who are on longer-interval LAIs (e.g., 3-month, 6-month intervals)?
- On telepsychiatry visits, what are some strategies that you have found effective to complete these exams?
 - What are some of the common challenges?

Recommendations: APA Guideline for Schizophrenia Treatment

- Regular assessment of patients for TD through clinical examination or through use of a structured evaluative tool
 - Clarifying their likely etiology
 - Monitoring their longitudinal course
 - Determining the effects of medication changes or treatments for TD
- There is no specific score threshold that suggests a need for intervention, although ranges of scores are noted to correspond with mild, moderate, and severe symptoms.
 - The same total score can be associated with significantly different clinical manifestations and varying impacts on the patient
- Patients, family /caregivers may be able to provide information about
 - Movement onset
 - Longitudinal course in relation to treatment or other precipitants
 - Impact on functioning and quality of life
 - Health status (including dentition)

APA. (2020). The American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia.
<https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines>

Recommendations: APA Guideline for Schizophrenia Treatment

Baseline

- Assessment with a structured instrument (e.g., AIMS, DISCUS) if such movements are present

Follow-up

- Assessments at minimum of **every 6 months** in patients at high risk of tardive dyskinesia
- At least **every 12 months** for other patients
 - Or **with new onset or exacerbation** of preexisting movements is detected at any visit

AIMS: www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/monitoring/AIMS.pdf

DISCUS: https://www.georgiacollaborative.com/wp-content/uploads/sites/15/2017/08/MP5671_sp_SECURED.pdf

Training video: <https://www.hmpgloballearningnetwork.com/site/pcn/multimedia/aims-exam-instructional-video>

APA. (2020). The American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia. <https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines>

Recommendations: LAI Workgroup

- Include AIMS at point of LAI injection in person
 - Within scope of MD, NP, RN, Pharmacist (and HCP can be trained)
- Via telepsychiatry, many of the elements of the AIMS can be covered
 - Consulting with any clinic staff (if present at visit)
 - Asking the patient if they have noticed any abnormal movements
 - Clinician's observations during the consultation
 - Observing various body regions
 - (e.g., eyes, lips, face, hands and fingers, shoulders) at rest and with activation is doable with telepsychiatry
 - Tongue usually can be examined quite well
 - Camera can be tilted down for the clinician to observe the patient's feet and toes
- Frequent assessment

References

- American Psychiatric Association. (2020). The American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia.
<https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines>
- Jain, R. Can the AIMS Exam be Conducted Via Telepsychiatry?
<https://www.hmpgloballearningnetwork.com/site/pcn/article/can-aims-exam-be-conducted-telepsychiatry#:~:text=If%20the%20patient%20is%20at,3>.
- SMI Adviser app. www.SMIAdviser.org/app

SMI Adviser LAI Center of Excellence

Clinical Tips
Educational Webinars
VF Recordings

*NEW*LAI Injection Videos

<https://smiadviser.org/about/lai>



Welcome to the Long-Acting Injectable (LAI) Center of Excellence (COE)

SMI Adviser created the LAI COE to promote the safe and effective use of LAIs. The ultimate goal of this effort is to improve the lives of individuals who have schizophrenia, schizoaffective, and bipolar disorders. The LAI COE provides clinicians with training opportunities, technical assistance, and vetted resources. These include:

- Live and on-demand webinars
- Virtual Learning Collaboratives
- Virtual Forums
- Email listserv
- On-demand consultations
- Intensive consultation to sites or communities
- Clinical tips and resources



The LAI COE is led by SMI Nursing Expert, Donna Rolin, PhD, APRN, SMI Adviser Physician Expert, Robert Cotes, MD, and SMI Adviser content partner, National Association of State Mental Health Program Directors (NASMHPD), and supported by members of the LAI Workgroup.

For individual and family resources on using long-acting injectables, visit the individual and family [Knowledge Base](#).

An APA and SAMHSA Initiative



SMI ADVISER MOBILE APP: Rating Scales, including AIMS




Download at SMIAdviser.org/app

An APA and SAMHSA Initiative



FEEDBACK

Please help us improve the Clozapine & LAI Virtual Forum by completing this survey:
<http://smiadvise.org/forumfeedback>



Pre-submit Cases/Related Questions

www.smiadvise.org/vfcases

UPCOMING VIRTUAL FORUM

Clozapine-Induced Sialorrhea and Botulinum Toxin

3/1/23 @4 – 4:45 PM ET

For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community

- www.smiadvise.org/cloz_lai_signup

An APA and SAMHSA Initiative

